Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$384K Sell
13,992
-7,708
-36% -$205K ﹤0.01% 1036
2026
Q1
$582K Buy
21,700
+1,135
+6% +$34K 0.01% 819
2025
Q4
$633K Buy
20,565
+5,055
+33% +$158K 0.01% 778
2025
Q3
$476K Buy
+15,510
New +$378K 0.01% 851
2025
Q1
Sell
-14,663
Closed -$306K 1196
2024
Q4
$306K Sell
14,663
-3,798
-21% -$83.4K 0.01% 937
2024
Q3
$552K Buy
18,461
+1,623
+10% +$43.4K 0.01% 734
2024
Q2
$423K Sell
16,838
-1,623
-9% -$46K 0.01% 801
2024
Q1
$552K Buy
18,461
+7,124
+63% +$209K 0.01% 734
2023
Q4
$361K Sell
11,337
-1,590
-12% -$49.9K 0.01% 829
2023
Q3
$456K Sell
12,927
-263
-2% -$10K 0.02% 709
2023
Q2
$501K Sell
13,190
-618
-4% -$24.6K 0.02% 645
2023
Q1
$521K Sell
13,808
-2,343
-15% -$90.1K 0.02% 638
2022
Q4
$684K Buy
16,151
+3,649
+29% +$150K 0.04% 476
2022
Q3
$402K Buy
12,502
+2,833
+29% +$99.5K 0.03% 553
2022
Q2
$314K Sell
9,669
-2,434
-20% -$78.9K 0.02% 611
2022
Q1
$438K Buy
12,103
+3,379
+39% +$116K 0.03% 500
2021
Q4
$345K Buy
8,724
+122
+1% +$5.09K 0.03% 496
2021
Q3
$376K Buy
8,602
+1,816
+27% +$81.5K 0.04% 428
2021
Q2
$277K Buy
+6,786
New +$262K 0.03% 462

Other funds holding GMAB

Ethic Inc's GMAB Position: Q2 2026 in Review

Ethic Inc reduced its Genmab (GMAB) stake by 36% in Q2 2026, selling an estimated $205K and leaving 13,992 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #1036.

Ethic Inc first reported a position in GMAB in Q2 2021 and has held it in 19 quarters since. The position peaked at $684K in Q4 2022. 73 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Ethic Inc held 13,992 shares of Genmab worth $384K as of Q2 2026.
  • Ethic Inc sold 7,708 Genmab shares in Q2 2026, an estimated $205K.
  • Genmab made up ﹤0.01% of Ethic Inc's portfolio in Q2 2026, its #1036 holding.
  • Ethic Inc first reported a position in Genmab in Q2 2021 and has held it in 19 quarters since.
  • Ethic Inc's Genmab position peaked at $684K in Q4 2022.
  • 73 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.